Search
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Research
The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Research
Statistical considerations for the platform trial in COVID-19 vaccine priming and boostingThe Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.
News & Events
Screen ORIGINS study finds mobile devices a lifeline for families during lockdownsA study of ORIGINS families has revealed a positive aspect to the COVID pandemic, with families found to benefit from the extra time together during lockdowns and mobile devices proving useful for helping them stay in touch with extended family and friends and for activities such as online classes.
News & Events
Assessing COVID-19 Across Western Australian SchoolsWestern Australia has been highly successful at containing community spread of COVID-19 to date.
With the number of COVID-19 infections in Western Australia continuing to grow – including confirmed cases in children – The Kids Research Institute Australia understands that our community is growing increasingly worried.
Thanks to 30 years of support from the WA community, The Kids Research Institute Australia is home to some of the world’s best researchers.
Research save lives and contains the spread of COVID-19.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.
Research
Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trialSome individuals have a persistence of symptoms following both COVID-19 (post-acute COVID-19 syndrome; PACS) and other viral infections. This study used prospectively collected data from an international trial to compare symptoms following COVID-19 and non-COVID-19 respiratory illness, to identify factors associated with the risk of PACS, and to explore symptom patterns before and after COVID-19 and non-COVID-19 respiratory illnesses.